Molecular dissection of the RAS/RAF/MAPK pathway in primary and metastatic melanoma.

被引：0
|
作者：
Rother, J. [1 ]
Bailey, J. [1 ]
Alvarado, G. [1 ]
Prieto, V. G. [1 ]
Lazar, A. J. [1 ]
Jones, D. [1 ]
Hwu, W. J. [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8050
引用
收藏
页码：465S / 465S
页数：1
相关论文
共 50 条
  • [21] Molecular and immunological Effects of MAPK Inhibitors in metastatic Melanoma
    Dinter, L.
    Karitzky, P.
    Tunger, A.
    Mueller, A.
    Kaeubler, T.
    Wehner, R.
    Niessner, H.
    Wanke, I.
    Beissert, S.
    Seliger, B.
    Schmitz, M.
    Meier, F.
    Westphal, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [22] Pulverizing Metastatic Melanoma Beyond the B-RAF and N-RAS Chunks
    Moschos, Stergios
    ONCOLOGIST, 2012, 17 : 6 - 6
  • [23] Molecular analysis of the PDGFRα-RAS/MAPK pathway in childhood medulloblastoma
    Langdon, JA
    Hernan, R
    Atkinson, J
    Gilbertson, RJ
    Clifford, SC
    BRITISH JOURNAL OF CANCER, 2003, 88 : S69 - S69
  • [24] MOLECULAR STUDY OF RAS/ MAPK PATHWAY GENES IN PATIENTS WITH CRYPTORCHIDISM
    Rodriguez, Fernando A.
    Vallejos, Carla
    Unanue, Nancy
    Hernandez, Maria I.
    Celis, Soledad
    Martin-Arenas, Ruben
    Palomares Bralo, Maria
    Heath, Karen E.
    Lopez, Maria T.
    Cassorla, Fernando
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 12 - 12
  • [25] Therapeutic targeting of Ras/Raf/MAPK pathway by natural products: A systematic and mechanistic approach for neurodegeneration
    Gravandi, Mohammad Mehdi
    Abdian, Sadaf
    Tahvilian, Maedeh
    Iranpanah, Amin
    Moradi, Seyed Zachariah
    Fakhri, Sajad
    Echeverria, Javier
    PHYTOMEDICINE, 2023, 115
  • [26] Ras/Raf/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.
    McGlynn, L. M.
    Kirkegaard, T.
    Tovey, S.
    Cameron, D.
    Twelves, C.
    Cooke, T. G.
    Barlett, J. M. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S135 - S135
  • [27] The need of detection of B-RAF mutation in metastatic melanoma. Presentation of our experience and review of the literature
    Diamantopoulos, P.
    Deskoulidi, P.
    Pistolas, K.
    Kydonakis, M.
    Korogiannos, A.
    Gkouveris, P.
    Petrakopoulou, T.
    Zarkadas, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 71 - 71
  • [28] Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma
    Favre, Gilles
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 321 - 336
  • [29] Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
    Kim, Kyoo Hyun
    Cho, Sungmin
    Jeong, Yeyeong
    Baek, Eun Sil
    Lee, Chung
    Ryu, Hyang-Joo
    Noh, Young Su
    Hong, Yoon-hee
    Chung, Kee Yang
    Roh, Mi Ryung
    Oh, Byung Ho
    Kim, Chang Gon
    Jung, Minkyu
    Shin, Sang Joon
    ONCOLOGIST, 2024, 29 (06): : e811 - e821
  • [30] Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma
    Yadav, Vipin
    Zhang, Xiaoyi
    Liu, Jiangang
    Estrem, Shawn
    Li, Shuyu Dan
    Gong, Xue-Qian
    Buchanan, Sean
    Henry, James R.
    Starling, James J.
    Peng, Sheng-Bin
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
12345